Lew Lim, the founder and CEO of VieLight is seen explaining the device in the video.
The technology is called transcranial and intranasal photobiomodulation (PBM). Initial, small-scale results, are promising.
Five people, with mild to moderate Alzheimer’s, used the headsets every day for 12 weeks. The headset frame, with four different LED cluster-heads and an LED that clips to the inside of the nostril, was turned on for 15 minutes a day.
After the three months, neuroscientists noticed some patients, who were not able to speak in full sentences, could now put sentences together. Patients also experienced improved sleep and reduced wandering.
From 2014 DIY Brain Hacking with Andrew Vladimirov Speaker Preview of Anticipating 2025
And a couple of short clips from the Virtual Future Salon, February 2016
What Andrew is suggesting in this next clip is pretty wild. Basically, that he wants neurostimulation to operate in the brain at the molecular level, similar to how drugs work. Target a receptor site with a unique waveform?!!!
Cognitive and emotional functions
LLLT via commercial low-power sources (such as FDA-cleared laser diodes and LEDs) is a highly promising, affordable, non-pharmacological alternative for improving cognitive function. LLLT delivers safe doses of light energy that are sufficiently high to modulate neuronal functions, but low enough to not result in any damage. In 2002, the FDA approved LLLT for pain relief in cases of head and neck pain, arthritis and carpal tunnel syndrome. LLLT has been used non-invasively in humans after ischemic stroke to improve neurological outcome. It also led to improved recovery and reduced fatigue after exercise. One LLLT stimulation session to the forehead, as reported by Schiffer et al. (2009), produced a significant antidepressant effect in depressed patients. No adverse side effects were found either immediately or at 2 or 4 weeks after LLLT. Thus, these beneficial LLLT treatments have been found to be safe in humans. Even though LLLT has been regarded as safe and received FDA approval for pain treatment, the use of transcranial lasers for cognitive augmentation should be restricted to research until further controlled studies support this application for clinical use.